Diagnosis and Treatment of Osteoporosis in CKD
By:
Matthew J. Damasiewicz Department of Nephrology, Monash Health, Clayton, Victoria, Australia and
Department of Medicine, Monash University, Clayton, Victoria, Australia

Search for other papers by Matthew J. Damasiewicz in
Current site
Google Scholar
PubMed
Close
and
Thomas L. Nickolas Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York

Search for other papers by Thomas L. Nickolas in
Current site
Google Scholar
PubMed
Close
  • Collapse
  • Expand
  • 1.

    Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res 9: 11371141, 1994 PubMed

  • 2.

    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. 285: 785795, 2001

  • 3.

    Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al.: Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). 69: 19451953, 2006

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al.: Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s changed and why it matters. Kidney Int 92: 2636, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Damasiewicz MJ, Ebeling PR: Management of mineral and bone disorders in renal transplant recipients. Nephrology (Carlton) 22: 6569, 2017 PubMed

  • 6.

    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385397, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Miller PD: Bone disease in CKD: A focus on osteoporosis diagnosis and management. Am J Kidney Dis 64: 290304, 2014 PubMed

  • 8.

    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 76: 1130, 2009

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al.: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70: 13581366, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Miller PD: Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am 41: 613628, 2012 PubMed

  • 11.

    West SL, Jamal SA, Lok CE: Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol Dial Transplant 27: 23842388, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Fahal IH: Uraemic sarcopenia: Aetiology and implications. Nephrol Dial Transplant 29: 16551665, 2014 PubMed

  • 13.

    Wagner J, Jhaveri KD, Rosen L, Sunday S, Mathew AT, Fishbane S: Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant 29: 146151, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Klawansky S, Komaroff E, Cavanaugh PF Jr, Mitchell DY, Gordon MJ, Connelly JE, et al.: Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14: 570576, 2003 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Nickolas TL, McMahon DJ, Shane E: Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17: 32233232, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Naylor KL, McArthur E, Leslie WD, Fraser L-A, Jamal SA, Cadarette SM, et al.: The three-year incidence of fracture in chronic kidney disease. Kidney Int 86: 810818, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Coco M, Rush H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 11151121, 2000 PubMed

  • 18.

    Isakova T, Craven TE, Scialla JJ, Nickolas TL, Schnall A, Barzilay J, et al.; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone 78: 2327, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Arneson TJ, Li S, Liu J, Kilpatrick RD, Newsome BB, St Peter WL: Trends in hip fracture rates in US hemodialysis patients, 1993-2010. Am J Kidney Dis 62: 747754, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Nair SS, Mitani AA, Goldstein BA, Chertow GM, Lowenberg DW, Winkelmayer WC: Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States. Clin J Am Soc Nephrol 8: 13361342, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Kim SM, Liu S, Long J, Montez-Rath ME, Leonard MB, Chertow GM: Declining rates of hip fracture in end-stage renal disease: Analysis from the 2003-2011 nationwide inpatient sample. J Bone Miner Res 32: 22972303, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Goto NA, Weststrate ACG, Oosterlaan FM, Verhaar MC, Willems HC, Emmelot-Vonk MH, et al.: The association between chronic kidney disease, falls, and fractures: A systematic review and meta-analysis. Osteoporos Int 31: 1329, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Vilaca T, Salam S, Eastell R: In reply to “Risks of hip and nonvertebral fractures in patients with CKD”. Am J Kidney Dis 77: 546547, 2021 PubMed

  • 24.

    Beaubrun AC, Kilpatrick RD, Freburger JK, Bradbury BD, Wang L, Brookhart MA: Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients. J Am Soc Nephrol 24: 14611469, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Kim SM, Long J, Montez-Rath M, Leonard M, Chertow GM: Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res 31: 18031809, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Damasiewicz MJ, Nickolas TL: Rethinking bone disease in kidney disease. JBMR Plus 2: 309322, 2018 PubMed

  • 27.

    Malluche HH, Mawad HW, Monier-Faugere M-C: Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26: 13681376, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al.: Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67: 559566, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, et al.: Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—A single-center cohort study. Nephrol Dial Transplant 27: 345351, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Yenchek RH, Ix JH, Shlipak MG, Bauer DC, Rianon NJ, Kritchevsky SB, et al.; Health, Aging, and Body Composition Study: Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7: 11301136, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust M-H, et al.: European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dialysis Transplant Official Publ European Dialysis Transpl Assoc - European Ren Assoc 36: 4259, 2020

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust M-H, et al.; European Renal Osteodystrophy (EUROD) workgroup; an initiative of the CKD-MBD working group of the ERA-EDTA; and the committee of Scientific Advisors and National Societies of the IOF: Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int 32: 23972405, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Hughes-Austin JM, Katz R, Semba RD, Kritchevsky SB, Bauer DC, Sarnak MJ, et al.: Biomarkers of bone turnover identify subsets of chronic kidney disease patients at higher risk for fracture. J Clin Endocrinol Metab 105: e2903e2911, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Jaques DA, Henderson S, Davenport A: Association between bone mineral density at different anatomical sites and both mortality and fracture risk in patients receiving renal replacement therapy: A longitudinal study. Clin Kidney J 15: 11881195, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Naylor KL, Garg AX, Zou G, Langsetmo L, Leslie WD, Fraser L-A, et al.: Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 10: 646653, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Jamal SA, West SL, Nickolas TL: The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int 25: 7176, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Przedlacki J, Buczyńska-Chyl J, Koźmiński P, Niemczyk E, Wojtaszek E, Gieglis E, et al.; Mazovia Fracture Study Group: The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: A two-year prospective multicenter cohort study. Osteoporos Int 29: 11051115, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Whitlock RH, Leslie WD, Shaw J, Rigatto C, Thorlacius L, Komenda P, et al.: The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. Kidney Int 95: 447454, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Nickolas TL, Stein E, Cohen A, Thomas V, Staron RB, McMahon DJ, et al.: Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 21: 13711380, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Trombetti A, Stoermann C, Chevalley T, Van Rietbergen B, Herrmann FR, Martin P-Y, et al.: Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int 24: 17211732, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Nickolas TL, Cremers S, Zhang A, Thomas V, Stein E, Cohen A, et al.: Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 22: 15601572, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Cejka D, Patsch JM, Weber M, Diarra D, Riegersperger M, Kikic Z, et al.: Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol 6: 22642271, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, et al.: Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28: 18111820, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Jamal S, Cheung AM, West S, Lok C: Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int 23: 28052813, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A, Eastell R: Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol 29: 15571565, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Pothuaud L, Carceller P, Hans D: Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: Applications in the study of human trabecular bone microarchitecture. Bone 42: 775787, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, et al.: A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31: 940948, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Iki M, Tamaki J, Kadowaki E, Sato Y, Dongmei N, Winzenrieth R, et al.: Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: The Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res 29: 399407, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Muschitz C, Kocijan R, Haschka J, Pahr D, Kaider A, Pietschmann P, et al.: TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone 79: 259266, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Luckman M, Hans D, Cortez N, Nishiyama KK, Agarawal S, Zhang C, et al.: Spine trabecular bone score as an indicator of bone microarchitecture at the peripheral skeleton in kidney transplant recipients. Clin J Am Soc Nephrol 12: 644652, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Naylor KL, Prior J, Garg AX, Berger C, Langsetmo L, Adachi JD, et al.: Trabecular bone score and incident fragility fracture risk in adults with reduced kidney function. Clin J Am Soc Nephrol 11: 20322040, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Malluche HH, Monier-Faugere MC, Blomquist G, Davenport DL: Two-year cortical and trabecular bone loss in CKD-5D: Biochemical and clinical predictors. Osteoporos Int 29: 125134, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Khairallah P, Nickolas TL: Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13: 962969, 2018 PubMed

  • 54.

    Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB: Incidence and mortality of hip fractures in the United States. JAMA 302: 15731579, 2009 PubMed

  • 55.

    Coen G, Mantella D, Manni M, Balducci A, Nofroni I, Sardella D, et al.: 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 68: 18401848, 2005 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, et al.: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 11151125, 2005 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446456, 2003 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al.: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307: 674684, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Wang AY-M, Fang F, Chan J, Wen Y-Y, Qing S, Chan IH-S, et al.: Effect of paricalcitol on left ventricular mass and function in CKD--The OPERA trial. J Am Soc Nephrol 25: 175186, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Khelifi N, Desbiens LC, Sidibé A, Mac-Way F: Vitamin D analogues and fracture risk in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. JBMR Plus 6: e10611, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Conley M, Lioufas N, Toussaint ND, Elder GJ, Badve SV, Hawley CM, et al.: Dietary phosphate consumption in australians with stages 3b and 4 chronic kidney disease. J Ren Nutr 31: 155163, 2021

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al.: Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-analysis. Lancet 382: 12681277, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Patel L, Bernard LM, Elder GJ: Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 11: 232244, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, et al.; EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 24822494, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, et al.; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators: Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE Trial. J Am Soc Nephrol 26: 14661475, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Tsuruta Y, Okano K, Kikuchi K, Tsuruta Y, Akiba T, Nitta K: Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 17: 120126, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, et al.: A randomized trial of cinacalcet versus vitamin d analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 10: 10311040, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME, et al.: Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87: 846856, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al.: Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial. JAMA 317: 156164, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Pires GO, Vieira IO, Hernandes FR, Teixeira AL, Oliveira IB, Dominguez WV, et al.: Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism. Bone 121: 277283, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B: Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18: 24012407, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Titan SM, Laureati P, Sang Y, Chang AR, Evans M, Trevisan M, et al.: Bisphosphonate utilization across the spectrum of eGFR. Arch Osteoporos 15: 69, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Damasiewicz MJ, Nickolas TL: Bisphosphonate therapy in CKD: The current state of affairs. Curr Opin Nephrol Hypertens 29: 221226, 2020 PubMed

  • 74.

    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res 20: 21052115, 2005 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al.: Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res 22: 503508, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: Post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol 18: 66, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Sugimoto T, Inoue D, Maehara M, Oikawa I, Shigematsu T, Nishizawa Y: Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: A post hoc subgroup analysis of a phase III trial in Japan. J Bone Miner Metab 37: 730740, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Bergner R, Henrich D, Hoffmann M, Schmidt-Gayk H, Lenz T, Upperkamp M: Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol 21: 510516, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Ali MS, Ernst M, Robinson DE, Caskey F, Arden NK, Ben-Shlomo Y, et al.: Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: An open cohort multivariable and propensity score analysis from Funen, Denmark. Arch Osteoporos 15: 81, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Fujita R, Ota M, Sato D, Nakazawa D, Kimura-Suda H, Nakamura F, et al.: Comparison of the efficacy and renal safety of bisphosphonate between low-dose/high-frequency and high-dose/low-frequency regimens in a late-stage chronic kidney disease rat model. Calcif Tissue Int 107: 389402, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Swallow EA, Aref MW, Metzger CE, Sacks S, Lehmkuhler DR, Chen N, et al.: Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing. Bone 127: 419426, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Schini M, Peel N, Toronjo-Urquiza L, Thomas E, Salam S, Khwaja A, et al.: Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis. Osteoporos Int 33: 737744, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Alarkawi D, Ali MS, Bliuc D, Pallares N, Tebe C, Elhussein L, et al.: Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: A population-based cohort study. J Bone Miner Res 35: 894900, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Robinson DE, Ali MS, Pallares N, Tebé C, Elhussein L, Abrahamsen B, et al.: Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: A bi-national cohort analysis. J Bone Miner Res 36: 820832, 2021

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Robinson DE, Ali MS, Strauss VY, Elhussein L, Abrahamsen B, Arden NK, et al.: Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: A propensity score-matched cohort study. Health Technol Assess 25: 1106, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al.; FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756765, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al.: Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26: 18291835, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S, et al.: Denosumab safety and efficacy among participants in the FREEDOM Extension Study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106: 397409, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Hiramatsu R, Ubara Y, Sawa N, Sakai A: Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: A 2-year observational study. Nephrol Dial Transplant 36: 19001907, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Dave V, Chiang CY, Booth J, Mount PF: Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. Am J Nephrol 41: 129137, 2015 PubMed

  • 91.

    Block GA, Bone HG, Fang L, Lee E, Padhi D: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27: 14711479, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Chen C-L, Chen N-C, Hsu C-Y, Chou K-J, Lee P-T, Fang H-C, et al.: An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99: 24262432, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, et al.: Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: A randomized controlled trial. Am J Transplant 16: 18821891, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Kobel C, Frey D, Graf N, Wüthrich RP, Bonani M: Follow-up of bone mineral density changes in de novo kidney transplant recipients treated with two doses of the receptor activator of nuclear factor κB ligand inhibitor denosumab. Kidney Blood Press Res 44: 12851293, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 14341441, 2001 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 20282039, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18: 5968, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Imai H, Watanabe M, Fujita T, Watanabe H, Harada K, Moritoyo T; ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 04 Study Group: Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: A pilot study. Int J Clin Pharmacol Ther 52: 166174, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Cejka D, Kodras K, Bader T, Haas M: Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study. Kidney Blood Press Res 33: 221226, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, Suwabe T, et al.: Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: A prospective study. Osteoporos Int 27: 14411450, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G: Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int 99: 489499, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Leder BZ, O’Dea LSL, Zanchetta JR, Kumar P, Banks K, McKay K, et al.: Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100: 697706, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al.; ACTIVE Study Investigators: Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA 316: 722733, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Moreira CA, Fitzpatrick LA, Wang Y, Recker RR: Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone 97: 314319, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Bilezikian JP, Hattersley G, Mitlak BH, Hu M-Y, Fitzpatrick LA, Dabrowski C, et al.: Abaloparatide in patients with mild or moderate renal impairment: Results from the ACTIVE phase 3 trial. Curr Med Res Opin 35: 20972102, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al.: Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375: 15321543, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al.: Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370: 412420, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al.: Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377: 14171427, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al.: Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet 390: 15851594, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, et al.: Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37: 14371445, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, Tsujimoto Y: Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39: 10821090, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Hara T, Hijikata Y, Matsubara Y, Watanabe N: Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. Cochrane Database Syst Rev 7: CD013424, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 750 733 316
Full Text Views 480 477 18
PDF Downloads 654 650 30